Enliven Therapeutics, Inc. SEC filings ELVN
Enliven Therapeutics, Inc. has 798 filings in SEC EDGAR's recent list, going back to Apr 21, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 30, 2024 | — |
| CORRESP | Letter to the SEC | Apr 26, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2024 | — |
| CORRESP | Letter to the SEC | Apr 18, 2024 | — |
| D | Filing | Apr 3, 2024 | — |
| EFFECT | Filing | Jul 3, 2023 | — |
| CORRESP | Letter to the SEC | Jun 29, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2023 | — |
| 425 | Filing | Feb 22, 2023 | — |
| 425 | Filing | Feb 13, 2023 | — |
| EFFECT | Filing | Jan 23, 2023 | — |
| CORRESP | Letter to the SEC | Jan 19, 2023 | — |
| CORRESP | Letter to the SEC | Jan 6, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2022 | — |
| CORRESP | Letter to the SEC | Dec 19, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2022 | — |
| 425 | Filing | Dec 5, 2022 | — |
| 425 | Filing | Oct 14, 2022 | — |
| 425 | Filing | Oct 13, 2022 | — |
| EFFECT | Filing | Apr 8, 2021 | — |
| CORRESP | Letter to the SEC | Apr 6, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2021 | — |
| EFFECT | Filing | Mar 11, 2020 | — |
| CERT | Filing | Mar 11, 2020 | — |
| CORRESP | Letter to the SEC | Mar 10, 2020 | — |
| 8-A12B | Filing | Mar 9, 2020 | — |
| CORRESP | Letter to the SEC | Mar 9, 2020 | — |
| CORRESP | Letter to the SEC | Mar 9, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 24, 2020 | — |
| CORRESP | Letter to the SEC | Feb 19, 2020 | — |
| CORRESP | Letter to the SEC | Feb 14, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2019 | — |
| DRSLTR | Filing | Oct 8, 2019 | — |
| DRS/A | Filing | Oct 8, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 10, 2019 | — |
| DRS | Filing | Aug 15, 2019 | — |
| D | Filing | Mar 29, 2019 | — |
| D | Filing | Apr 21, 2016 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1672619
- Former names
- IMARA Inc. (until Feb 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.